SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

CORRESP Filing

ENvue Medical, Inc.
Date: May 14, 2025 · CIK: 0001326706 · Accession: 0001641172-25-010211

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-284973

Date
May 14, 2025
Author
DAWSON JAMES
Form
CORRESP
Company
ENvue Medical, Inc.

Letter

Dawson James Securities, Inc.

North Federal Highway, Suite 600

Boca Raton, Fl 33432

May 14, 2025

VIA EDGAR CORRESPONDENCE

U.S. Securities and Exchange Commission

Division of Corporation Finance

F Street, N.E. Washington, D.C. 20549

Re: NanoVibronix, Inc. Registration Statement on Form S-1/A

File No. 333-284973

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the "Act"), we, the placement agent, hereby request that the Securities and Exchange Commission (the "Commission") take appropriate action to cause the above-referenced registration statement on Form S-1/A (the "Registration Statement") to become effective at 4:00 p.m., Eastern Time, on Wednesday, May 14, 2025 or as soon thereafter as practicable.

Pursuant to Rule 460 under the Act, we wish to advise you that we have distributed as many copies of the Preliminary Prospectus dated May 14, 2025 to agents, dealers, institutions and others as appears to be reasonable to secure adequate distribution of the preliminary prospectus.

The undersigned, as placement agent, has complied and will comply with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

If you require any additional information with respect to this letter, please contact Ali Panjwani at (212) 326-0820 of Pryor Cashman LLP.

Very truly yours,
DAWSON JAMES
SECURITIES, INC.

Show Raw Text
CORRESP
 1
 filename1.htm

 Dawson
James Securities, Inc.

 101
North Federal Highway, Suite 600

 Boca
Raton, Fl 33432

 May
14, 2025

 VIA
EDGAR CORRESPONDENCE

 U.S.
Securities and Exchange Commission

 Division
of Corporation Finance

 100
F Street, N.E. Washington, D.C. 20549

 Re: NanoVibronix,
 Inc.
 Registration Statement on Form S-1/A

 File
No. 333-284973

 Ladies
and Gentlemen:

 Pursuant
to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the "Act"), we, the placement
agent, hereby request that the Securities and Exchange Commission (the "Commission") take appropriate action to cause the
above-referenced registration statement on Form S-1/A (the "Registration Statement") to become effective at 4:00 p.m., Eastern
Time, on Wednesday, May 14, 2025 or as soon thereafter as practicable.

 Pursuant
to Rule 460 under the Act, we wish to advise you that we have distributed as many copies of the Preliminary Prospectus dated May 14,
2025 to agents, dealers, institutions and others as appears to be reasonable to secure adequate distribution of the preliminary prospectus.

 The
undersigned, as placement agent, has complied and will comply with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

 If
you require any additional information with respect to this letter, please contact Ali Panjwani at (212) 326-0820 of Pryor Cashman LLP.

 Very truly yours,

 DAWSON JAMES
 SECURITIES, INC.

 By:
 /s/
 Robert D. Keyser, Jr.

 Robert D. Keyser, Jr.

 Chief Executive Officer

 cc: M.
 Ali Panjwani, Esq.

 Pryor
Cashman LLP